Abbott Laboratories (ABT)

Outperform Recap: Q2 2026

The Acceleration Arrives: Abbott Beats, Raises, and Rips 11% as the Ex-Deal Growth Question Resolves

Outperform Recap: Q1 2026

The Plan Is Working, the Stock Isn't: Exact Sciences Closes, EP Accelerates, Nutrition Volume Turns — Maintaining Outperform at a Fresh Low

Outperform Recap: Q4 2025

A Nutrition Air Pocket Sparks a 10% Drop; the EPS Algorithm, a Diagnostics Inflection, and Exact Sciences Are Intact — Upgrading to Outperform

Hold Recap: Q3 2025

An In-Line Quarter, a Confident 2026 Preview, and an Upgrade on Deck: Maintaining Hold

Hold Recap: Q2 2025

A Beat the Tape Hated: The Device Engine Roars, Diagnostics Drags, and a Trimmed Guide Ceiling Resets a Premium Multiple — Initiating at Hold